| Autor: |
FJ García-Moreno, Roberto Collado-Borrell, María Olmedo, Maricela Valerio, Elena Lobato-Matilla, Beatriz Somoza-Fernandez, Ana Herranz, Juan Carlos Lopez-Bernaldo-de-Quirós, Teresa Aldámiz-Echevarría, Silvia Manrique-Rodríguez, Emilio Bouza, Sebastian Garcia-Sanchez, Irene Taladriz-Sender, RM Romero-Jiménez, Marina Machado, Paula Ruiz-Briones, Patricia Muñoz, Cecilia M. Fernández-Llamazares, Rafael Correa-Rocha, Milagros Sancho-Gonzalez, José Luis Revuelta-Herrero, Camino Sarobe-González, Alvaro Gimenez-Manzorro, CG Rodriguez-Gonzalez, Esther Chamorro-de-Vega, María Sanjurjo |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Expert Review of Clinical Pharmacology
article-version (VoR) Version of Record |
| ISSN: |
1751-2441
1751-2433 |
| DOI: |
10.1080/17512433.2021.1875819 |
| Popis: |
Background: We report the long-term outcomes, changes in laboratory parameters, the incidence of secondary nosocomial infections and treatment cost of a Spanish cohort of patients with severe COVID-19 that received tocilizumab (TCZ). Methods: Retrospective cohort of PCR confirmed adult patients who received TCZ from March 1 to 24, 2020 in a tertiary hospital was analyzed. Patients were followed up until 10 May 2020. Results: We included 162 patients (median age 64 years; 70.4% male). At time of TCZ administration, 48.1% of patients were on invasive mechanical ventilation (IMV). Over a median follow-up of 53 days, 46.9% of patients were discharge in good conditions and 19.8% were still hospitalized. The overall mortality was 33.3%, being higher in patients on IMV than those who did not (46.2% vs 26.7%, P |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
